CareDx (CDNA) Plans Public Offering of Common Stock

September 20, 2016 4:02 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. CareDx also expects to grant to the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares will be offered and sold by CareDx.

Piper Jaffray & Co. is acting as sole manager for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering.

The public offering will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-206277) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on December 4, 2015.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Equity Offerings

Related Entities

Piper Jaffray, S3

Add Your Comment